Proteomics analysis in Alzheimer's disease: New insights into mechanisms of neurodegeneration

International Review of Neurobiology

Volumn 61, Issue , 2003, Pages 161-188

  Butterfield, D Allan ^a,b   Boyd Kimball, Debra ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME;

ALZHEIMER DISEASE; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; HUMAN; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; NERVE DEGENERATION; PROTEIN DATABASE; PROTEOMICS; REVIEW; TRANSGENIC ANIMAL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ALZHEIMER DISEASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DATABASES, PROTEIN; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION; HUMANS; MASS SPECTROMETRY; NERVE DEGENERATION; PROTEOME; PROTEOMICS;

EID: 33845434935     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (118)

1. Aebersold, R., and Goodlett, D. R. (2001). Mass spectrometry in proteomics. Chem. Rev. 101, 269-295.
2. Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., and Markesbery, W. R. (2000). Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74, 2520-2527.
3. Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., Geddes, J. W., and Markesbery, W. R. (2001). Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373-383.
4. Aksenov, M. Y., Tucker, H. M., Nair, P., Askenova, M. V., Butterfield, D. A., Estus, S., and Markesbery, W. R. (1999). The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase in different brain regions in Alzheimer's disease brain. Neurochem. Res. 24, 767-774.
5. Anthony, S. G., Schipper, H. M., Tavares, R., Hovanesian, V., Cortez, S. G., Stopa, E. G., and Johanson, C. E. (2003). Stress protein expression in the Alzheimer-diseased choroid plexus. J. Alzheimer's Dis. 5, 171-177.
6. Austen, B. M., Frears, E. R., and Davies, H. (2000). The use of Seldi ProteinChip arrays to monitor production of Alzheimer's β-amyloid in transfected cells. J. Peptide Sci. 6, 459-469.
7. Bajo, M., Yoo, B. C., Cairns, N., Gratzer, M., and Lubec, G. (2001). Neurofilament proteins NF-L, NF-M, and NF-H in brain of patients with Down syndrome and Alzheimer's disease. Amino Acids 21, 293-301.
8. Balcz, B., Kirchner, L., Cairns, N., Fountoulakis, M., and Lubec, G. (2001). Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J. Neural. Transm. 61(Suppl.), 193-201.
9. Beher, D., Wrigley, J. D., Owens, A. P., and Shearman, M. S. (2002). Generation of C-terminally truncated amyloid β-peptides is dependent on γ-secretase activity. J. Neurochem. 82, 563-575.
10. Berggren, K. N., Schulenberg, B., Lopez, M. F., Steinberg, T. H., Bogdanova, A., Smejkal, G., Wang, A., and Patton, W. F. (2002). An improved formulation of SYPRO ruby protein gel stain: Comparison with the original formulation and with a ruthenium II tris (bathophenanthroline disulfonate) formulation. Proteomics 2, 486-498.
11. Blass, J. P., and Gibson, G. E. (1991). The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev. Neurol. 147, 513-525.
12. Bush, A. I. (2003). The metallobiology of Alzheimer's disease. Trends Neurosci. 26, 207-214.
13. Butterfield, D. A. (2002). Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer's disease brain. Fret Radic. Res. 36, 1307-1313.
14. Butterfield, D. A. (2003). Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: Mechanisms and consequences. Curr. Med. Chem. 10, 2651-2659.
15. Butterfield, D. A. (2004). Proteomics: A new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Research 1000, 1-7.
16. Butterfield, D. A., and Castegna, A. (2003a). Proteomic analysis of oxidatively modified proteins in Alzheimer's disease brain: Insights into neurodegeneration. Cell Mol. Biol. 49, 747-751.
17. Butterfield, D. A., and Castegna, A. (2003b). Proteomics for the identification of specifically oxidized proteins in brain: Technology and application to the study of neurodegenerative disorders. Amino Acids 25, 419-125.
18. Butterfield, D. A., and Castegna, A. (2003c). Energy metabolism in Alzheimer's disease brain: Insights from proteomics. Appl. Proteomics Genomics 2, 67-70.
19. Butterfield, D. A., and Lauderback, C. M. (2002). Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Rod. Biol Med. 32, 1050-1060.
20. Butterfield, D. A., and Stadtman, E. R. (1997). Protein oxidation processes in aging brain. Adv. Cell. Aging Gerontol. 2, 161-191.
21. Butterfield, D. A., Castegna, A., Lauderback, C. M., and Drake, J. (2002). Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 23, 655-664.
22. Butterfield, D. A., Drake, J., Porcernich, C., and Castegna, A. (2001). Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol. Med. 7, 548-554.
23. Butterfield, D. A., Boyd-Kimball, D., and Castegna, A. (2003). Proteomics in Alzheimer's disease: Insights into potential mechanisms of neurodegeneration. J. Neurochem. 86, 1313-1327.
24. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchett, D. R., Price, D. L., and Wong, P. C. (2001). BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 4, 233-234.
25. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G., Burkhard, P., Hochstrasser, D. F., and Sanchez, J. C. (2003). A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzeimer's disease. Proteomics 3, 1486-1494.
26. Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R., and Butterfield, D. A. (2002a). Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. I. Creatine kinase BB, glutamine synthetase, and ubiquitin carboxy-terminal hydrolase L-1. Free Rad. Biol. Med. 33, 562-571.
27. Castegna, A., Aksenov, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R., and Butterfield, D. A. (2002b). Proteomics identification of oxidatively modified proteins in Alzheimer's disease brain. II. Dihydropyrimidinase related protein II, α-enolase, and heat schock cagnate 71. J. Neurochem. 82, 1524-1532.
28. Castegna, A., Thongboonkerd, V., Klein, J. B., Lynn, B., Markesbery, W. R., and Butterfield, D. A. (2003). Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85, 1391-1401.
29. Castegna, A., Thongboonkerd, V., Klein, J., Lynn, B. C., Wang, Y. L., Osaka, H., Wada, K., and Butterfield, D. A. (2004). Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl terminal hydrolase L-1, reveals oxidation of key proteins. J. Neurochem. 88, 1540-1546.
30. Chen, F., Yang, D. S., Petanceska, S., Yang, A., Tandon, A., Yu, G., Rozmahel, R., Ghiso, J., Nishimura, M., Zhang, D. M., Kawarai, T., Leveeque, G., Mills, J., Levesque, L., Song, Y. Q., Rogaeva, E., Wastaway, D., Mount, H., Gandy, S., St. George-Hyslop, P., and Fraser, P. E. (2000). Carboxy-terminal fragments of Alzheimer's β-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenillin 1-deficient cells. J. Biol. Chem. 275, 36794-36802.
31. Cheon, M. S., Fountoulakis, M., Cairns, N., Dierssen, M., Herkner, K., and Lubec, G. (2001). Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease. J. Neurol. Transm. 61(Suppl.), 281-288.
32. Choe, L. H., Dutt, M. J., Relkin, N., and Lee, K. H. (2002). Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23, 2247-2251.
33. Choi, J., Malakowsky, C. A., Talent, J. M, Conrad, C. C., Carrll, C. A., Weintraub, S. T., and Gracy, R. W. (2003). Antiapoptotic proteins are oxidized by Aβγ5-35 in Alzheimer's fibroblasts. Biochim. Biophys. Acta 1637, 135-141.
34. Coleman, P. D., and Flood, D. G. (1987). Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol. Aging 8, 521-545.
35. Davidsson, P., Westman-Brinkmalm, A., Nilsson, C. L., Lindbjer, M., Paulson, L., Andreasen, N., Sjogren, M., and Blennow, K. (2002). Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Clin. Neurosci. Neuropathol. 13, 611-615.
36. De Hoffmann, E. (1996). Tandem mass spectrometry: A primer. J. Mass Spectrom. 31, 129-137.
37. Engidawork, E., Gulesserian, T., Balic, N., Cairns, N., and Lubec, G. (2001a). Changes in nicotinic acetylcholine receptor subunits expression in brain of patients with Down syndrome and Alzheimer's disease. J. Neurol. Transm. 61(Suppl.), 211-222.
38. Engidawork, E., Gulesserian, T., Yoo, B. C., Cairns, N., and Lubec, G. (2001b). Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem. Biophys. Res. Commun. 281, 84-93.
39. Engidawork, E., Gulesserian, T, Seidl, R., Cairns, N., and Lubec, G. (2001c). Expression of apoptosis-related proteins in brains of patients with Alzheimer's disease. Neurosci. Lett. 303, 79-82.
40. Ferguson, P. L., and Smith, R. D. (2003). Proteome analysis by mass spectrometry. Annu. Rev. Biophys. Biomol. Struct. 32, 399-424.
41. Friso, G., and Wikstrom, L. (1999). Analysis of proteins from membrane-enriched cerebellar preparations by two-dimensional gel electrophoresis and mass spectrometry. Electrophoresis 20, 917-927.
42. Gastard, M. C., Troncoso, J. C., and Koliasos, V. E. (2003). Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol. 54, 393-398.
43. Gauss, G., Kalkum, M., Lowe, M., Lehrach, H., and Klose, J. (1999). Analysis of the mouse proteome. I. Brain proteins: Separation by two-dimensional electrophoresis and identification by mass spectrometry and genetic varation. Electrophoresis 20, 575-600.
44. Giacobini, E. (2003). Cholinergic function and Alzheimer's disease. Int. J. Geriatr. Pychiatr. 18, S1-S5.
45. Goldstein, L. E., Muffat, J. A., Chemy, R. A., Moir, R. D., Ericsson, M. H., Huang, X., Mavros, C., Coccia J. A., Faget, K. Y., Fitch, K. A., Masters, C. L., Tanzi, R. E., Chylack, L. T., Jr., and Bush, A. I. (2003). Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 361, 1258-1265.
46. Good, P. F., Werner, P., Hsu, A., Olanow, C., and Perl, D. P. (1996). Evidence for neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149, 21-27.
47. Goshe, M. B., Conrads, T. P., Panisko, E. A., Angell, N. H., Veenstra, T. D., and Smith, R. D. (2001). Phosphoprotein isotope-coded affinity tag approach for isolating and quantitating phosphopeptides in proteome-wide analyses. Anal. Chem. 73, 2578-2586.
48. Greber, S., Lubec, G., Cairns, N., and Fountoulakis, M. (1999). Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 20, 928-934.
49. Gygi, S. P., Rist, B., Gerber, S. A., Tureck, F., Gelb, M. H., and Aebersold, R. (1999). Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999.
50. Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, P., Wu, J. F., Carney, J. M., Lovell, M., Markesbery, W. R., and Butterfield, D. A. (1995). Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146-2156.
51. Herbert, B. (1999). Advances in protein solubilization for two-dimensional gel electrophoresis. Electrophoresis 20, 660-663.
52. Herbert, B. R., Molloy, M. P., Gooley, A. A., Walsh, B. J., Bryson, W. G., and Williams, K. L. (1998). Improved protein solubility in two-dimensional electrophoresis using tributyl phosphine as reducing agent. Electrophoresis 19, 845-851.
53. Hoving, S., Gerrits, B., Voshol, H., Muller, D., Roberts, R. C., and Oostrum, J. V. (2002). Preparative two-dimensional gel electrophoresis at alkaline pH using narrow range immobilized pH gradients. Proteomics 2, 127-134.
54. Issaq, H. J., Conrads, T. P., Janini, G. M., and Veenstra, T. D. (2002a). Methods for fractionation, separation, and profiling of proteins and peptides. Electrophoresis 23, 3048-3061.
55. Issaq, H. J., Veenstra, T. D., Conrads, T. P., and Felschow, D. (2002b). The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 292, 587-592.
56. Katzman, R., and Saitoh, T. (1991). Advances in Alzheimer's disease. FASEB J. 5, 278-286.
57. Keller, J. N., Hanni, K. B., and Markesbery, W. M. (2000). Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75, 436-439.
58. Kim, S. H., and Lubec, G. (2001). Brain α-endosulfine is manifold decreased in brains from patients with Alzheimer's disease: A tentative marker and drug target? Neurosci. Lett. 310, 77-80.
59. Kim, S. H., Cairns, N., Fountoulakis, M., and Lubec, G. (2001a). Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neurosci. Lett. 300, 41-14.
60. Kim, S. H., Fountoulakis, M., Cairns, N., and Lubec, G. (2001b). Protein levels of human peroxiredoxin subtypes in brains of Alzheimer's disease and Down syndrome. J. Neural. Transm. Suppl. 61, 223-235.
61. Kim, S. H., Fountoulakis, M., Cairns, N. J., and Lubec, G. (2002). Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem. Biophys. Res. Commun. 296, 970-975.
62. Kim, S. H., Nairn, A. C., Cairns, N., and Lubec, G. (2001c). Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease. J. Neural. Transm. 61(Suppl.), 263-272.
63. Kim, S. H., Vlkolinsky, R., Cairns, N., Fountoulakis, M., and Lubec, G. (2001d). The reduction of NADH ubiquinone oxidoreducatase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci. 68, 2741-2750.
64. Kim, S. H., Vlkolinský, R., Cairns, N., and Lubec, G. (2000). Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol. Life Sci. 57, 1810-1816.
65. Knight, Z. A., Schilling, B., Row, R. H., Kenski, D. M., Gibson, B. W., and Shokat, K. M. (2003). Phosphospecific proteolysis for mapping sites of protein phosphorylation. Nat. Biotechnol. 21, 1047-1054.
66. Krapfenbauer, K., Engidawork, E., Cairns, N., Fountoulakis, M., and Lubec, G. (2003). Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 967, 152-160.
67. Larsen, M. R., Sorensen, G. L., Fey, S. J., Larsen, P. M., and Poepstorff, P. (2001). Phosphoproteomics: Evaluation of the use of enzymatic de-phosphorylation and differential mass spectrometric peptide mass mapping for site specific phosphorylation assignment in proteins separated by gel electrophoresis. Proteomics 1, 223-238.
68. Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R., and Butterfield, D. A. (2001). The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of Abeta 1-42. J. Neurochem. 78, 413-416.
69. Lewczuk, P., Esselmann, H., Meyer, M., Wollscheid, V., Neumann, M., Otto, M., Maler, J. M., Ruther, E., Komhuber, J., and Wiltfang, J. (2003). The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: Evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Comm. Mass Spectrum. 17, 1291-1296.
70. Lovell, M. A., and Markesbery, W. R. (2001). Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch. Neurol. 58, 392-396.
71. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., and Markesbery, W. R. (1998). Copper, iron, and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52.
72. Lubec, G., Nonaka, M., Krapfenbauer, K., Gratzer, M., Cairns, N., and Fountoulakis, M. (1999). Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J. Neural. Transm. 57(Suppl.), 161-177.
73. March, R. E. (1997). An introduction to quadrupole ion trap mass spectrometry. J. Mass Spectrom. 32, 351-369.
74. Mark, R. J., Lovell, M. A., Markesbery, W. R., Uchida, K., and Mattson, M. P. (1997). A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68, 255-264.
75. Markesbery, W. R. (1997). Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147.
76. Masliah, E., Alford, M., De Teresa, R., Mallory, M., and Hansen, L. (1995). Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 40, 759-766.
77. Merchant, M., and Weinberger, S. R. (2000). Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21, 1164-1167.
78. Molloy, M. P., Herbert, B. R., Walsh, B. J., Tyler, M. I., Traini, M., Sanchez J. C., Hochstrasser, D. F., Williams, K. L., and Gooley, A. A. (1998). Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis. Electrophoresis 19, 837-844.
79. Molloy, M. P. (2000). Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal. Biochem. 280, 1-10.
80. Morishima, Y., Gotoh, Y., Zeig, J., Barrett, T., Takano, H., Flavell, R., Davis, R. J., Shirasaki, Y., and Greenberg, M. E. (2001). Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun-N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 7551-7560.
81. Moseley, M. A. (2001). Current trends in differential expression proteomics: Isotopically coded tags. Trends Biotechnol. 19, S10-S16.
82. Nagele, R. G., D'Andrea, M. R., Anderson, W. J., and Wang, H. Y. (2002). Intracellular accumulation of β-amyloid (1-42) in neurons is facilitated by the α7 nicotinic receptor in Alzheimer's disease. Neuroscience 110, 199-211.
83. Oda, Y., Nagasu, T., and Chait, B. T. (2001). Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat. Biotechnol. 19, 379-382.
84. Ojika, K., Tsugu, Y., Mitake, S., Otsuka, Y., and Takada, E. (1998). NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro. Neuroscience 101, 341-352.
85. Pasquali, C., Fialka, I., and Huber, L. A. (1997). Preparative two-dimensional gel electrophoresis of membrane proteins. Electrophoresis 18, 2573-2581.
86. Prange, A., Schaumlöffel, D., Brätter, P., Richarx, A., and Wolf, C. (2001). Species analysis of metallothionein isoforms in human brain cytosols by use of capillary electrophoresis hyphenated to inductively coupled plasma-sector field mass spectrometry. J. Anal. Chem. 371, 764-774.
87. Qian, W. J., Goshe, M. B., Camp, D. G., III, Yu, L. R., Tang, K., and Smith, R. D. (2003). Phosphoprotein isotope-coded solid-phase tag approach for enrichment and quantitative analysis of phosphopcptidcs from complex mixtures. Anal. Chem. 75, 5441-5450.
88. Rabilloud, T. (1998). Use of thiourea to increase the solubility of membrane proteins in two-dimensional electrophoresis. Electrophoresis 19, 758-760.
89. Rossor, M. N., Svendsen, C., Hunt, S. P., Mountjoy, C. Q., Roth, M., and Iversen, L. L. (1982). The substantia innominata in Alzheimer's disease: A histochemical and biochemical study of cholinergic marker enzymes. Neurosci. Lett. 28, 217-222.
90. Santoni, V., Molloy, M., and Rabilloud, T. (2000). Membrane proteins and proteomics: Un amour impossible? Electrophoresis 21, 1054-1070.
91. Scheltens, P., and Korf, E. S. C. (2000). Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. Curr. Opin. Neurol. 13, 391-396.
92. Schonberger, S. J., Edgar, P. F., Kydd, R., Faull, R. L. M., and Cooper, G. J. S. (2001). Proteomic analysis of the brain in Alzheimer's disease: Molecular phenotype of a complex disease process. Proteomics 1, 1519-1528.
93. Schuller, E., Gulesserian, T., Seidl, R., Cairns, N., and Lubec, G. (2001). Brain t-complex polypeptide 1 (TCP-1) related to its natural substrate β1 tubulin is decreased in Alzheimer's disease. Life Sci. 69, 263-270.
94. Selkoe, D. J., and Podlisny, M. B. (2002). Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Ceramics Hum. Genet. 3, 67-99.
95. Selkoe, D. J. (2001a). Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers Dis. 3, 75-80.
96. Selkoe, D. J. (2001b). Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 11039-11041.
97. Shim, K. S., and Lubec, G. (2002). Drebrin, a dendritic protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci. Lett. 324, 209-212.
98. Shringarpure, R., Grune, T., and Davies, K. J. (2001). Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells. Cell Mol. Life Sci. 58, 1442-1450.
99. Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., and Perry, G. (1997). Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17, 2653-2657.
100. Soreghan, B. A., Yang, F., Thomas, S. N., Hsu, J., and Yang, A. J. (2003a). High-throughput proteomic-based identification of oxidatively induced protein carbonylation in mouse brain. Pharm. Res. 20, 1713-1720.
101. Soreghan, B. A., Thomas, S. N., Dull, K. E., and Yang, A. J. (2003b). Identification of oxidatively induced protein carbonylation in an APP/PS1 mouse model of Alzheimer's disease by a shotgun proteomics approach. Soc. Neurosci. Abs. 629.22.
102. Steinberg, T. H., Agnew, B. J., Gee, K. R., Laung, W. Y., Goodman, T, Schulenberg, B., Hendrickson, J., Beechem J. M., Haugland, R. P., and Patton, W. F. (2003). Global quantitative phosphorylation analysis using multiplexed proteomics technology. Proteomics 3, 1128-1144.
103. Stevens, S. M., Jr., Zharikova, A. D., and Prokai, L. (2003). Proteomic analysis of the synaptic plasma membrane fraction isolated from rate forebrain. Mol. Brain Res. 117, 116-128.
104. Subramaniam, R., Roediger, F., Jordan, B., Mattson, M. P., Keller, J. N., Waeg, G., and Butterfield, D. A. (1997). The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 69, 1161-1169.
105. Tilleman, K., Stevens, I., Spittaels, K., Van der Haute, C., Clerens, S., Van den Bergh, G., Geerts, H., Van Lauven, F., Vandesande, F., and Moens, L. (2002a). Differential expression of brain proteins in glycogen synthase kinasc-3β transgenic mice: A proteomics point of view. Proteomics 2, 94-104.
106. Tilleman, K., Van den Haute, C., Geerts, H., van Leuvcn, G., Esmans, E. L, and Moens, L. (2002b). Proteomics analysis of the neurodegenerarion in the brain of tau transgenic mice. Proteomics 2, 656-665.
107. Tsuji, T., Shimohama, S., Kamiya, S., Sazuka, T., and Ohara, O. (1999). Analysis of brain proteins in Alzheimer's disease using high-resolution two-dimensional gel electrophoresis. J. Neurol. Sci. 166, 100-106.
108. Tozaki, H., Matsumoto, A., Kanno, T, Nagai, K., Nagata, T., Yamamoto, S., and Nishizaki, T. (2002). The inhibitory and facilitatory actions of amyloid-beta peptide on nicotinic ACh receptors and AMPA receptors. Biachem. Biophys. Res. Commun. 294, 42-45.
109. Tsuji, T, Shiozaki, A., Kohno, R., Yoshizato, K., and Shimohama, S. (2002). Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem. Res. 27, 1245-1253.
110. Ueno, I., Sakai, T., Yamaoka, M., Yoshida, R., and Tsugita, A. (2000). Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection. Electrophoresis 21, 1832-1845.
111. Vlkolinský, R., Cairns, N., Fountoulakis, M., and Lubec, G. (2001). Decreased brain levels of 2′,3-cyclic nucleotidc-3′- phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol. Aging 22, 547-553.
112. Wagner, Y., Sickmann, A., Meyer, H. E., and Daum, G. (2003). Multidimensional nano-HPLC for analysis of protein complexes. J. Am. Soc. Mass Spectrom. 14, 1003-1011.
113. Wang, H., and Hanash, S. (2003). Multi-dimensional liquid phase separations in proteomics. J. Chromatogr. B. 787, 11-18.
114. Washburn, M. P., Wolters, D., and Yates, J. R. (2001). Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19, 242-247.
115. Wu, C. C., MacCoss, M. J., Howell, K. E., and Yates, J. R., III (2003). A method for the comprehensive proteomic analysis of membrane proteins. Nat. Biotechnol. 21, 532-538.
116. Yatin, S. M., Varadarajan, S., and Butterfield, D. A. (2000). Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimers Dis. 2, 123-131.
117. Yoo, B. C., Fountoulakis, M., Cairns, N., and Lubec, G. (2001a). Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 22, 172-179.
118. Yoo, B. C., Kim, S. H., Cairns, N., Fountoulakis, M., and Lubec, G. (2001b). Deranged expression of molecular chaperones in brains of patients with Alzheimer's disease. Biochem. Biophys. Res. Commun. 280, 249-258.